TB-500
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
TB-500 is the systemic half of the recovery toolkit — where BPC-157 acts locally and fast, TB-500 is the body-wide “repair coordinator.” It’s a synthetic fragment of thymosin beta-4 (Tβ4), a natural protein your cells use to manage their internal scaffolding (actin) and to orchestrate the cell movement that wound healing depends on. People use it for whole-body recovery, soft-tissue repair, and flexibility, most often paired with BPC-157 in the “Wolverine” stack.
Tβ4 was first isolated in 1981 by Dr. Allan Goldstein at the National Institutes of Health from calf thymus tissue — and it turned out to be one of the most abundant proteins inside human cells, found at elevated concentration wherever the body is actively healing (wound sites, torn tendons, damaged muscle). That observation — Tβ4 piling up at injury sites — is what kicked off four decades of research asking whether the protein causes repair or just shows up because of it. The mechanism work below is what answered that question.
The framing worth keeping: TB-500 is a repair accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, recovery. On that foundation, the biology is genuinely interesting and the preclinical record is broad. The rest of this article walks the mechanism, what the research shows at each tier (including an honest note on which molecule the human trials used), the protocol people run, and the open questions.
What does it do in my body?
Actin sequestration — the core, best-understood mechanism. Tβ4 grabs free actin monomers (the building blocks of the cell’s internal skeleton) and releases them on demand [PMID 12852258, 17468232]. That control over the cytoskeleton is what lets cells crawl — and migration is the heart of repair: cells have to move into damaged tissue before they can rebuild it. This is also why TB-500 pairs naturally with BPC-157, which drives the local angiogenesis the migrating cells need.
Angiogenesis. Tβ4 promotes new blood vessel formation, increasing perfusion to repairing tissue [PMID 22074294, 27450736].
Anti-inflammatory + anti-fibrotic signaling. Tβ4 down-regulates inflammatory chemokines/cytokines (via NF-κB suppression), reduces TGF-β-driven fibrosis, inhibits the fibroblast-to-myofibroblast conversion that creates scar, and lowers macrophage infiltration [PMID 36580759]. Much of the anti-fibrotic punch may live in a small N-terminal metabolite, ac-SDKP, which has reduced (and in some models reversed) fibrosis in liver, lung, heart, and kidney. This anti-scar-tissue property is part of why TB-500 is emphasized for post-surgical recovery specifically — excess scar formation is a major recovery complication, and TB-500’s profile pushes toward organized repair over fibrosis.
Stem/progenitor activation + cell survival. Tβ4 mobilizes and matures stem/progenitor cells and protects cells from apoptosis [PMID 22074294].
A transparency note on the molecule — and a real labeling trap. Historically “TB-500” meant a shorter synthetic fragment (the active LKKTETQ region) of full Tβ4, and a portion of the active wound-healing biology may reside in specific metabolites. But the term is used inconsistently across vendors: some clinics still use “TB-500” to mean the 7-amino-acid fragment, while higher-tier product (including Alyve’s) is the full 43-amino-acid acetylated thymosin beta-4 sequence — the actual parent molecule the published research is on. Practical takeaway: when you see a study, check whether it used full/recombinant Tβ4 or the fragment — they overlap heavily in mechanism but aren’t identical — and when you buy, confirm which molecule the vial actually contains. That’s a reason to read both the evidence and the COA carefully, not a reason to discount the peptide.
How can it help me?
- Best fit: Systemic recovery support, often stacked with BPC-157 (the “Wolverine” pairing)
- Where the science stands: Deep, mechanistically coherent animal/in-vitro record; human data exists for clinical-grade Tβ4 (eye drops, wound, cardiac)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
TB-500 is well-tolerated in the available data, with no serious toxicity signal.
- Injection-site reactions (redness, swelling, irritation) — most common; rotate sites, clean technique.
- Mild headache or transient lethargy — occasionally reported.
- No detectable effect in a minority of users — sometimes a product-quality issue (the gray-market fragment’s actual content varies, which is exactly what a COA solves).
- Cancer caution — the same angiogenesis/cell-migration biology that drives repair overlaps mechanistically with tumor biology, so suspected or active malignancy is a sensible contraindication to discuss with an oncologist. This is mechanism-based caution, not documented human harm — and note the anti-fibrotic/anti-inflammatory arms of Tβ4 cut the other way. Pregnancy is also commonly listed as a contraindication.
The largest real-world variable isn’t the side-effect profile — it’s whether the vial contains correctly-dosed, identity-confirmed TB-500 in the first place, which is the supply-chain point below.
Regulatory status: Not FDA-approved for any use. Prohibited by WADA and a well-known doping agent in horse racing (its cytoskeletal/cell-movement effects). The FDA reopened consideration of peptide-compounding policy in 2026, but no approval exists for TB-500. Sold legally as a research chemical, “not for human consumption.” Note that the clinical-grade Tβ4 programs (RGN-259, rhTB4) are separate regulated drug-development efforts and don’t confer approval on the gray-market fragment.
Worth noting the signal value of the equine ban specifically: published methods exist for detecting TB-500 in horse urine and plasma — people watching elite-racehorse injury-recovery timelines (with millions of dollars on the line) decided this molecule warranted a dedicated detection protocol. That’s not proof of human athletic-recovery efficacy, but it is a meaningful inference about what the people closest to high-value soft-tissue injuries believe.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
Reconstitution (objective math). A 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL (5,000 mcg/mL). On a U-100 insulin syringe, a 500 mcg dose = 0.1 mL = 10 units. Add water slowly down the vial wall, swirl gently, never shake; refrigerate reconstituted.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
Two common dosing conventions — and they differ, which is worth knowing:
- Cheat-sheet / clinic convention (one practitioner): 10 mg vial in 2 mL, 500 mcg dosed AM, daily, 8 weeks on / off.
- Forum loading protocol: a loading phase of 2–5 mg twice weekly for the first 4–6 weeks, then a lower-frequency maintenance dose (e.g., 2–5 mg once weekly or every other week). This is a much higher per-injection amount than the cheat-sheet’s daily 500 mcg.
The two reflect different philosophies — daily microgram dosing vs. front-loaded milligram dosing leaning on Tβ4’s longer half-life. Both are in real-world use; the loading-then-maintenance pattern is the more commonly cited approach for TB-500 specifically, because the molecule lasts longer than BPC-157 and doesn’t need daily injections. There’s no human dose-finding trial for the fragment to anchor either, so these are community-converged protocols, stated plainly as such.
What should I avoid combining — and what's synergistic?
A third, increasingly-cited convention is stacked daily dosing inside the Wolverine pairing: 300–500 mcg of TB-500 alongside 300–500 mcg of BPC-157, daily, often mixed in one vial. When TB-500 is run solo on the loading pattern, the common shorthand is 2–5 mg twice weekly with 1–2-week breaks between cycles. Note one onset detail worth setting expectations for: some users report mild flu-like symptoms or transient lethargy in the first week of TB-500 — early-onset and self-limiting, not a sign the peptide isn’t working.
Stacking. TB-500 + BPC-157 is the classic Wolverine stack (Wolverine (BPC-157 + TB-500)) — systemic migration/repair (TB-500) plus local angiogenesis and FAK-paxillin healing (BPC-157). Add GHK-Cu for GLOW (collagen/skin layer) or KPV for KLOW (immune/anti-inflammatory layer). Some users keep the peptides in separate vials over a denaturing-on-mixing concern; co-dosing from separate syringes sidesteps it.
How can I buy this?
Alyve sells TB-500 as a lyophilized research powder, 10 mg at $59 (a 5 mg variant is currently out of stock). The 10 mg lot (TBS339) carries a third-party Certificate of Analysis from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity): 99.06% purity, identity confirmed as Thymosin Beta-4.
That identity confirmation matters more for TB-500 than almost anything, precisely because of the fragment-vs-full-Tβ4 and content-variability issues above. The gray market is rough — independent testing has found roughly 1 in 4 research peptides underdosed, mislabeled, or contaminated (often with leftover TFA salt), frequently with no COA. A large 2026 gray-market purity analysis (Mendias et al., preprint — 6,441 samples across 14 compounds, TB-500 among them) puts hard numbers under that variability. A verified >99%-pure, LC-MS-identity-confirmed product is the clean tier, and the lab report is the proof that what’s in the vial is actually Thymosin Beta-4.
Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. TB-500’s loading-then-maintenance dosing burns through product over a cycle, so a 3-bottle order (or a Wolverine-stack bundle with BPC-157) is how committed users buy.
TB-500 is also carried by AminoClub — use code OHM for 20% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
| Class | Synthetic peptide, a fragment of the natural 43-amino-acid protein thymosin beta-4 (Tβ4) |
| Mechanism (one line) | Sequesters actin to drive cell migration, plus angiogenesis and anti-inflammatory/anti-fibrotic signaling — the systemic “repair coordinator” |
| Route / frequency | Subcutaneous / intramuscular; often a loading phase then maintenance |
| Half-life | Longer-acting than BPC-157 (why it’s dosed less frequently); precise human PK for the fragment |
| Evidence base | Deep, mechanistically coherent animal/in-vitro record; human data exists for clinical-grade Tβ4 (eye drops, wound, cardiac) |
| Safety record | Well-tolerated in available studies; no serious toxicity signal; mild injection-site reactions most common |
| Regulatory status | Not FDA-approved; WADA-banned; a major doping agent in horse racing |
| Alyve product | TB-500 10 mg ($59) · COA 99.06%, identity confirmed Thymosin Beta-4 (lot TBS339) · OHM-15 |
| Best-fit user | Systemic recovery support, often stacked with BPC-157 (the “Wolverine” pairing) |
What it is
TB-500 is the systemic half of the recovery toolkit — where BPC-157 acts locally and fast, TB-500 is the body-wide “repair coordinator.” It’s a synthetic fragment of thymosin beta-4 (Tβ4), a natural protein your cells use to manage their internal scaffolding (actin) and to orchestrate the cell movement that wound healing depends on. People use it for whole-body recovery, soft-tissue repair, and flexibility, most often paired with BPC-157 in the “Wolverine” stack.
Tβ4 was first isolated in 1981 by Dr. Allan Goldstein at the National Institutes of Health from calf thymus tissue — and it turned out to be one of the most abundant proteins inside human cells, found at elevated concentration wherever the body is actively healing (wound sites, torn tendons, damaged muscle). That observation — Tβ4 piling up at injury sites — is what kicked off four decades of research asking whether the protein causes repair or just shows up because of it. The mechanism work below is what answered that question.
The framing worth keeping: TB-500 is a repair accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, recovery. On that foundation, the biology is genuinely interesting and the preclinical record is broad. The rest of this article walks the mechanism, what the research shows at each tier (including an honest note on which molecule the human trials used), the protocol people run, and the open questions.
How it works
Actin sequestration — the core, best-understood mechanism. Tβ4 grabs free actin monomers (the building blocks of the cell’s internal skeleton) and releases them on demand [PMID 12852258, 17468232]. That control over the cytoskeleton is what lets cells crawl — and migration is the heart of repair: cells have to move into damaged tissue before they can rebuild it. This is also why TB-500 pairs naturally with BPC-157, which drives the local angiogenesis the migrating cells need.
Angiogenesis. Tβ4 promotes new blood vessel formation, increasing perfusion to repairing tissue [PMID 22074294, 27450736].
Anti-inflammatory + anti-fibrotic signaling. Tβ4 down-regulates inflammatory chemokines/cytokines (via NF-κB suppression), reduces TGF-β-driven fibrosis, inhibits the fibroblast-to-myofibroblast conversion that creates scar, and lowers macrophage infiltration [PMID 36580759]. Much of the anti-fibrotic punch may live in a small N-terminal metabolite, ac-SDKP, which has reduced (and in some models reversed) fibrosis in liver, lung, heart, and kidney. This anti-scar-tissue property is part of why TB-500 is emphasized for post-surgical recovery specifically — excess scar formation is a major recovery complication, and TB-500’s profile pushes toward organized repair over fibrosis.
Stem/progenitor activation + cell survival. Tβ4 mobilizes and matures stem/progenitor cells and protects cells from apoptosis [PMID 22074294].
A transparency note on the molecule — and a real labeling trap. Historically “TB-500” meant a shorter synthetic fragment (the active LKKTETQ region) of full Tβ4, and a portion of the active wound-healing biology may reside in specific metabolites. But the term is used inconsistently across vendors: some clinics still use “TB-500” to mean the 7-amino-acid fragment, while higher-tier product (including Alyve’s) is the full 43-amino-acid acetylated thymosin beta-4 sequence — the actual parent molecule the published research is on. Practical takeaway: when you see a study, check whether it used full/recombinant Tβ4 or the fragment — they overlap heavily in mechanism but aren’t identical — and when you buy, confirm which molecule the vial actually contains. That’s a reason to read both the evidence and the COA carefully, not a reason to discount the peptide.
What the research shows
Animal / preclinical — first-class evidence, and this is the bulk of the picture. The preclinical record is mechanistically coherent and spans many organ systems. Strongest first:
- Cardiac repair across models [PMID 27450736, 36709593] — Tβ4 reduces infarct volume, preserves cardiac function, increases vessel growth, and reduces fibrosis after ischemic injury; in adult mouse explants it reactivated epicardial progenitor cells toward vasculature [PMID 17495252].
- Anti-fibrotic switch [PMID 36580759] — benefit in liver, lung, heart, and kidney fibrosis models, with ac-SDKP carrying much of the activity.
- Dermal / wound healing [PMID 20536453, 40279568] — faster dermal healing including in diabetic and aged animals and burns.
- NAFLD inflammation [PMID 40322536] — Tβ4 promoted protective M2 macrophage polarization and reduced liver inflammation; knockdown worsened steatosis.
- Kidney injury [PMID 27575556] — endogenous Tβ4 acts as a brake on glomerular injury; its loss accelerated inflammation and fibrosis.
- Neuro / anti-inflammatory mechanisms [PMID 31612500, 36834849] — TLR/NF-κB modulation, NLRP3 inflammasome suppression, autophagy induction.
Human evidence — exists, for clinical-grade Tβ4, and it’s mixed-but-real. This is the honest part most sources gloss:
- rhTB4 in STEMI heart attack (RCT, n=96, 2025) [PMID 41229390] — pharmaceutical recombinant human Tβ4 after stenting. The overall infarct-area difference vs placebo was not statistically significant, though an early-dosing subgroup (n=43) did show reduced infarct area. The authors call for larger trials. Honest read: a near-miss with a promising signal, not a slam-dunk and not a failure.
- Tβ4 eye drops (RGN-259), dry eye + neurotrophic keratopathy [PMID 30063853] — Phase 2 showed meaningful symptom/sign improvement; Phase 3 trials advanced. Well-tolerated.
- Dermal-wound Phase 2 (pressure/stasis ulcers, epidermolysis bullosa) [PMID 27450738] — accelerated repair, reported safe and well tolerated (disaggregated stats not in the review).
These human trials used clinical-grade Tβ4, not the gray-market TB-500 fragment — an important distinction for honesty. The fragment’s musculoskeletal/sports-recovery uses are supported by mechanism and user experience, not by a dedicated human RCT yet.
Where the evidence is genuinely contested — shown honestly: a 2012 knockout study found Tβ4 is dispensable for normal mouse cardiac development and function [PMID 22158707], which challenges the strongest “Tβ4 is an essential regenerator” developmental claims (the authors suggest earlier shRNA-knockdown studies may have had off-target effects). This doesn’t negate the therapeutic (added exogenous Tβ4) findings — a molecule can be dispensable at baseline yet beneficial when supplied at injury — but it’s a real nuance that tempers the most sweeping regeneration framing. Expert reads differ accordingly: the regenerative-medicine groups (Goldstein/Kleinman/Sosne lineage) treat the repair biology as well-established, while more conservative clinicians note that the strongest human signals are in eye and wound indications, not the recovery use TB-500 is sold for. Both are looking at the same data; the gap is how far they extrapolate to the injectable fragment.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Reconstitution (objective math). A 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL (5,000 mcg/mL). On a U-100 insulin syringe, a 500 mcg dose = 0.1 mL = 10 units. Add water slowly down the vial wall, swirl gently, never shake; refrigerate reconstituted.
Two common dosing conventions — and they differ, which is worth knowing:
- Cheat-sheet / clinic convention (one practitioner): 10 mg vial in 2 mL, 500 mcg dosed AM, daily, 8 weeks on / off.
- Forum loading protocol: a loading phase of 2–5 mg twice weekly for the first 4–6 weeks, then a lower-frequency maintenance dose (e.g., 2–5 mg once weekly or every other week). This is a much higher per-injection amount than the cheat-sheet’s daily 500 mcg.
The two reflect different philosophies — daily microgram dosing vs. front-loaded milligram dosing leaning on Tβ4’s longer half-life. Both are in real-world use; the loading-then-maintenance pattern is the more commonly cited approach for TB-500 specifically, because the molecule lasts longer than BPC-157 and doesn’t need daily injections. There’s no human dose-finding trial for the fragment to anchor either, so these are community-converged protocols, stated plainly as such.
A third, increasingly-cited convention is stacked daily dosing inside the Wolverine pairing: 300–500 mcg of TB-500 alongside 300–500 mcg of BPC-157, daily, often mixed in one vial. When TB-500 is run solo on the loading pattern, the common shorthand is 2–5 mg twice weekly with 1–2-week breaks between cycles. Note one onset detail worth setting expectations for: some users report mild flu-like symptoms or transient lethargy in the first week of TB-500 — early-onset and self-limiting, not a sign the peptide isn’t working.
Stacking. TB-500 + BPC-157 is the classic Wolverine stack (Wolverine (BPC-157 + TB-500)) — systemic migration/repair (TB-500) plus local angiogenesis and FAK-paxillin healing (BPC-157). Add GHK-Cu for GLOW (collagen/skin layer) or KPV for KLOW (immune/anti-inflammatory layer). Some users keep the peptides in separate vials over a denaturing-on-mixing concern; co-dosing from separate syringes sidesteps it.
Side effects & management
TB-500 is well-tolerated in the available data, with no serious toxicity signal.
- Injection-site reactions (redness, swelling, irritation) — most common; rotate sites, clean technique.
- Mild headache or transient lethargy — occasionally reported.
- No detectable effect in a minority of users — sometimes a product-quality issue (the gray-market fragment’s actual content varies, which is exactly what a COA solves).
- Cancer caution — the same angiogenesis/cell-migration biology that drives repair overlaps mechanistically with tumor biology, so suspected or active malignancy is a sensible contraindication to discuss with an oncologist. This is mechanism-based caution, not documented human harm — and note the anti-fibrotic/anti-inflammatory arms of Tβ4 cut the other way. Pregnancy is also commonly listed as a contraindication.
The largest real-world variable isn’t the side-effect profile — it’s whether the vial contains correctly-dosed, identity-confirmed TB-500 in the first place, which is the supply-chain point below.
Regulatory status
Not FDA-approved for any use. Prohibited by WADA and a well-known doping agent in horse racing (its cytoskeletal/cell-movement effects). The FDA reopened consideration of peptide-compounding policy in 2026, but no approval exists for TB-500. Sold legally as a research chemical, “not for human consumption.” Note that the clinical-grade Tβ4 programs (RGN-259, rhTB4) are separate regulated drug-development efforts and don’t confer approval on the gray-market fragment.
Worth noting the signal value of the equine ban specifically: published methods exist for detecting TB-500 in horse urine and plasma — people watching elite-racehorse injury-recovery timelines (with millions of dollars on the line) decided this molecule warranted a dedicated detection protocol. That’s not proof of human athletic-recovery efficacy, but it is a meaningful inference about what the people closest to high-value soft-tissue injuries believe.
The Alyve product
Alyve sells TB-500 as a lyophilized research powder, 10 mg at $59 (a 5 mg variant is currently out of stock). The 10 mg lot (TBS339) carries a third-party Certificate of Analysis from Freedom Diagnostics Testing (HPLC-UV purity + LC-MS identity): 99.06% purity, identity confirmed as Thymosin Beta-4.
That identity confirmation matters more for TB-500 than almost anything, precisely because of the fragment-vs-full-Tβ4 and content-variability issues above. The gray market is rough — independent testing has found roughly 1 in 4 research peptides underdosed, mislabeled, or contaminated (often with leftover TFA salt), frequently with no COA. A large 2026 gray-market purity analysis (Mendias et al., preprint — 6,441 samples across 14 compounds, TB-500 among them) puts hard numbers under that variability. A verified >99%-pure, LC-MS-identity-confirmed product is the clean tier, and the lab report is the proof that what’s in the vial is actually Thymosin Beta-4.
Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. TB-500’s loading-then-maintenance dosing burns through product over a cycle, so a 3-bottle order (or a Wolverine-stack bundle with BPC-157) is how committed users buy.
Sources
- PMIDs 41229390, 22158707, 30063853, 27450738, 27450736, 22074294, 36580759, 12852258, 17468232, 17495252, 40322536, 27575556, 36709593, 31612500, 36834849, 40279568.
- Innerbody, The Conversation (McGuire MD), Jeffrey Peng MD, Prisk MD.
- (lot TBS339).
- Mendias 2026 gray-market peptide-purity preprint (TB-500 included in the 6,441-sample analysis).
- Video digests: Huberman/Bakri peptides (2026-06-01, TB-500 / Wolverine sections); Holyfield Wolverine personal case studies (2026-06-08, stacked dosing / flu-like onset / anti-scar emphasis); Durst/Golombiewski BPC-157+TB-500 healing clinic protocol (2026-06-08, clinic-default combo + TB-4/TB-500 nomenclature); Sean PeptideAtoZ “Why Was TB-500 Banned?” (2026-06-16, ) — adds the Goldstein-1981-NIH discovery story, the “cellular logistics peptide” repositioning handle, and the racehorse-detection-protocol signal-value reframe.
Related: BPC-157 · Wolverine (BPC-157 + TB-500) · GLOW · KLOW.